Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Evolving insights into viral hepatitis : Advances, evidence, and expert perspectives from the ESCMID Study Group for Viral Hepatitis (ESGVH) Part 1: hepatitis A, E, and herpesvirus-associated liver disease

Săndulescu, Oana ; Matičič, Mojca ; Garcia, Federico ; Blomé, Marianne Alanko LU ; Mondelli, Mario U. ; Irving, William ; Zidovec-Lepej, Snjezana ; Widell, Anders LU and Şahin, Gülşen Özkaya LU (2025) In GERMS 15(3). p.254-262
Abstract

Viral hepatitis remains a global health concern, with growing recognition of the impact of hepatitis A virus (HAV), hepatitis E virus (HEV), and herpesvirus-associated hepatitis, particularly in vulnerable groups. This narrative review from the ESCMID Study Group for Viral Hepatitis (ESGVH) summarizes recent advances and expert perspectives. For HAV, insights into viral evolution, epidemiology, and risk groups underline the preventable nature of severe disease. HEV is increasingly recognized as both a hepatotropic and a systemic pathogen, with expanding knowledge on natural and vaccine-induced immunity. Herpesvirus-associated hepatitis, while rare, poses significant challenges, especially in patients with immunosuppression or during... (More)

Viral hepatitis remains a global health concern, with growing recognition of the impact of hepatitis A virus (HAV), hepatitis E virus (HEV), and herpesvirus-associated hepatitis, particularly in vulnerable groups. This narrative review from the ESCMID Study Group for Viral Hepatitis (ESGVH) summarizes recent advances and expert perspectives. For HAV, insights into viral evolution, epidemiology, and risk groups underline the preventable nature of severe disease. HEV is increasingly recognized as both a hepatotropic and a systemic pathogen, with expanding knowledge on natural and vaccine-induced immunity. Herpesvirus-associated hepatitis, while rare, poses significant challenges, especially in patients with immunosuppression or during pregnancy, where early suspicion and empirical antiviral therapy can be lifesaving. Collectively, these evolving insights highlight the importance of strengthened diagnostics, targeted prevention, and tailored management strategies to mitigate the burden of these underappreciated but clinically significant causes of viral hepatitis.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
HAV, hepatitis A, hepatitis E, herpesvirus, HEV, liver, Viral hepatitis
in
GERMS
volume
15
issue
3
pages
9 pages
publisher
European Academy of HIV/AIDS and Infectious Diseases
external identifiers
  • pmid:41334126
  • scopus:105027750845
ISSN
2248-2997
DOI
10.18683/germs.2025.1472
language
English
LU publication?
yes
id
c232a04d-0d22-4f6e-9d6c-50d6d0f616af
date added to LUP
2026-02-27 11:16:55
date last changed
2026-08-30 14:23:23
@article{c232a04d-0d22-4f6e-9d6c-50d6d0f616af,
  abstract     = {{<p>Viral hepatitis remains a global health concern, with growing recognition of the impact of hepatitis A virus (HAV), hepatitis E virus (HEV), and herpesvirus-associated hepatitis, particularly in vulnerable groups. This narrative review from the ESCMID Study Group for Viral Hepatitis (ESGVH) summarizes recent advances and expert perspectives. For HAV, insights into viral evolution, epidemiology, and risk groups underline the preventable nature of severe disease. HEV is increasingly recognized as both a hepatotropic and a systemic pathogen, with expanding knowledge on natural and vaccine-induced immunity. Herpesvirus-associated hepatitis, while rare, poses significant challenges, especially in patients with immunosuppression or during pregnancy, where early suspicion and empirical antiviral therapy can be lifesaving. Collectively, these evolving insights highlight the importance of strengthened diagnostics, targeted prevention, and tailored management strategies to mitigate the burden of these underappreciated but clinically significant causes of viral hepatitis.</p>}},
  author       = {{Săndulescu, Oana and Matičič, Mojca and Garcia, Federico and Blomé, Marianne Alanko and Mondelli, Mario U. and Irving, William and Zidovec-Lepej, Snjezana and Widell, Anders and Şahin, Gülşen Özkaya}},
  issn         = {{2248-2997}},
  keywords     = {{HAV; hepatitis A; hepatitis E; herpesvirus; HEV; liver; Viral hepatitis}},
  language     = {{eng}},
  number       = {{3}},
  pages        = {{254--262}},
  publisher    = {{European Academy of HIV/AIDS and Infectious Diseases}},
  series       = {{GERMS}},
  title        = {{Evolving insights into viral hepatitis : Advances, evidence, and expert perspectives from the ESCMID Study Group for Viral Hepatitis (ESGVH) Part 1: hepatitis A, E, and herpesvirus-associated liver disease}},
  url          = {{http://dx.doi.org/10.18683/germs.2025.1472}},
  doi          = {{10.18683/germs.2025.1472}},
  volume       = {{15}},
  year         = {{2025}},
}